

CORRECTION TO APPENDIX 3Y – DIRECTOR’S INTEREST NOTICE – ALISTAIR BENNALLACK

MELBOURNE (AUSTRALIA) 11 May 2026: Invion Limited (ASX: IVX) (“Invion” or the “Company”) wishes to advise that, due to an administrative oversight, an indirect interest held by Alistair Bennallack through a superannuation fund was not disclosed in the Appendix 3Y lodged on 24 July 2025.

The Company further notes that this indirect superannuation holding was also not included in the Appendix 3X lodged in connection with Alistair Bennallack’s appointment as a director on 22 October 2020.

The omission relates solely to an indirect interest held via a superannuation fund, comprising a relatively small parcel of 12,963 ordinary shares, and does not relate to any on-market transaction following the director’s appointment.

An updated Appendix 3Y reflecting the correct position has been lodged with the ASX concurrently with this announcement.

The Company is aware of its obligations regarding the disclosure of director holdings under ASX Listing Rule 3.19A. A standing agenda item at each Board meeting includes the review of a schedule of directors’ interests. The Company considers this to be an isolated administrative error.

This announcement was approved for release by the Board of Directors.

Sign up at Invion’s Investor Hub to receive regular updates, provide feedback and participate in discussions: <https://investors.inviongroup.com/>

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.inviongroup.com.

About Next Generation Photodynamic Therapy (NGPDT)

Invion is developing Photosoft™ technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells

For personal use only

ASX ANNOUNCEMENT

and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	INVION LIMITED
ABN	76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alistair Bennallack
Date of last notice	24 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Devils Magic Pty Ltd <A & J Retirement Fund A/C>, of which Mr Bennallack is a Director.
Date of change	11 May 2026
No. of securities held prior to change	<u>Direct</u> 235,147 Ordinary shares 181,064 Listed share options
Class	Ordinary shares
Number acquired	12,963 Ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<u>Direct</u> 235,147 Ordinary shares 181,064 Listed Share Options. <u>Indirect</u> 12,963 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Holding at director's date of appointment to the Board was not disclosed

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	N/A
---	-----

For personal use only

+ See chapter 19 for defined terms.